Subunit vaccine efficacy against Botulinum neurotoxin subtypes

Vaccine

Volumn 29, Issue 44, 2011, Pages 7688-7695

  Henkel, James S ^a   Tepp, William H ^b   Przedpelski, Amanda ^a   Fritz, Robert B ^a,c   Johnson, Eric A ^b   Barbieri, Joseph T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c His research interests involve social media and political engagement   (United States)

Author keywords

Botulinum neurotoxin serotype A; Botulism; Subunit vaccine; Synaptic vesicles; Vaccination

Indexed keywords

BOTULINUM TOXIN A; IMMUNOGLOBULIN; SUBUNIT VACCINE;

ANTIBODY TITER; ARTICLE; BOTULISM; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HOST; IMMUNE RESPONSE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN DOMAIN; RECEPTOR BINDING; SURVIVAL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; BACTERIAL VACCINES; BOTULINUM TOXINS, TYPE A; BOTULISM; CROSS PROTECTION; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED ICR; PROTEIN SUBUNITS; SURVIVAL ANALYSIS; VACCINES, SUBUNIT;

EID: 80053597280     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.134     Document Type: Article

References (57)

1. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982, 46(March (1)):86-94.
2. Lacy D.B., Stevens R.C. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999, 291(September (5)):1091-1104.
3. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82(September-October (9-10)):955-966.
4. Arndt J.W., Jacobson M.J., Abola E.E., Forsyth C.M., Tepp W.H., Marks J.D., et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 2006, 362(September (4)):733-742.
5. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2008, 70(May (19)):1707-1714.
6. Brinkac L.M., Davidsen T., Beck E., Ganapathy A., Caler E., Dodson R.J., et al. Pathema: a clade-specific bioinformatics resource center for pathogen research. Nucleic Acids Res 2009, 38(January (Database issue)):D408-D414.
7. Willems A., East A.K., Lawson P.A., Collins M.D. Sequence of the gene coding for the neurotoxin of Clostridium botulinum type A associated with infant botulism: comparison with other clostridial neurotoxins. Res Microbiol 1993, 144(September (7)):547-556.
8. Dineen S.S., Bradshaw M., Karasek C.E., Johnson E.A. Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol Lett 2004, 235(June (1)):9-16.
9. Lin G., Tepp W.H., Pier C.L., Jacobson M.J., Johnson E.A. Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl Environ Microbiol 2010, 76(January (1)):40-47.
10. Henkel J.S., Jacobson M., Tepp W., Pier C., Johnson E.A., Barbieri J.T. Catalytic properties of botulinum neurotoxin subtypes A3 and A4 (dagger). Biochemistry 2009, 48(March (11)):2522-2528.
11. Pier C.L., Chen C., Tepp W.H., Lin G., Janda K.D., Barbieri J.T., et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett 2011, 585(January (1)):199-206.
12. Torii Y., Kiyota N., Sugimoto N., Mori Y., Goto Y., Harakawa T., et al. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon 2011, 57(January (1)):93-99.
13. Edmond B.J., Guerra F.A., Blake J., Hempler S. Case of infant botulism in Texas. Tex Med 1977, 73(October (10)):85-88.
14. Leighton G.R. Report to the Scottish board of health 1923, H.M. Stationery Office, London.
15. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007, 27(4):303-318.
16. Dover N., Barash J.R., Arnon S.S. Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J Clin Microbiol 2009, 47(July (7)):2349-2350.
17. Carter A.T., Paul C.J., Mason D.R., Twine S.M., Alston M.J., Logan S.M., et al. Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum. BMC Genomics 2009, 10:115.
18. Jacobson M.J., Lin G., Tepp W., Dupuy J., Stenmark P., Stevens R.C., et al. Purification, modeling and analysis of neurotoxin BoNT/A5 from Clostridium botulinum strain A661222. Appl Environ Microbiol 2011, April.
19. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem Sci 1986, 11(August (8)):314-317.
20. Stenmark P., Dupuy J., Imamura A., Kiso M., Stevens R.C. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 2008, 4(8):e1000129.
21. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sato K., et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 1996, 378(January (3)):253-257.
22. Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A., Chapman E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 2003, 162(September (7)):1293-1303.
23. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312(April (5773)):592-596.
24. Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 2008, 19(December (12)):5226-5237.
25. Fu Z., Chen C., Barbieri J.T., Kim J.J., Baldwin M.R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 2009, May.
26. Smith L.A., Jensen M.J., Montgomery V.A., Brown D.R., Ahmed S.A., Smith T.J. Roads from vaccines to therapies. Mov Disord 2004, 19(March (Suppl. 8)):S48-S52.
27. Fiock M.A., Cardella M.A., Gearinger N.F. Studies on immunity to toxins of Clostridium botulinum. Ix. Immunologic response of man to purified pentavalent abcde botulinum toxiod. J Immunol 1963, 90(May):697-702.
28. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995, 63(July (7)):2738-2742.
29. Byrne M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998, 66(October (10)):4817-4822.
30. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76(March (3)):1314-1318.
31. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004, 572(August (1-3)):299-306.
32. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27(November (Suppl. 4)):D33-D39.
33. Aoki K.R., Smith L.A., Atassi M.Z. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010, 30(2):167-187.
34. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005, 73(October (10)):6998-7005.
35. Dux M.P., Huang J., Barent R., Inan M., Swanson S.T., Sinha J., et al. Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastoris. Protein Expres Purif 2011, 75(February (2)):177-185.
36. Zichel R., Mimran A., Keren A., Barnea A., Steinberger-Levy I., Marcus D., et al. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol 2010, 17(May (5)):784-792.
37. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75(June (6)):3043-3054.
38. Lee J.C., Hwang H.J., Sakaguchi Y., Yamamoto Y., Arimitsu H., Tsuji T., et al. C terminal half fragment (50kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol Immunol 2007, 51(4):445-455.
39. Park J.B., Simpson L.L. Progress toward development of an inhalation vaccine against botulinum toxin. Expert Rev Vaccines 2004, 3(August (4)):477-487.
40. Schiavo G., Shone C.C., Bennett M.K., Scheller R.H., Montecucco C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J Biol Chem 1995, 270(May (18)):10566-10570.
41. Webb R.P., Smith T.J., Wright P., Brown J., Smith L.A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 2009, 27(July (33)):4490-4497.
42. Pier C.L., Tepp W.H., Bradshaw M., Johnson E.A., Barbieri J.T., Baldwin M.R. Recombinant holotoxoid vaccine against botulism. Infect Immun 2008, 76(January (1)):437-442.
43. Shyu R.H., Shaio M.F., Tang S.S., Shyu H.F., Lee C.F., Tsai M.H., et al. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci 2000, 7(January-February (1)):51-57.
44. Li N., Yu Y.Z., Yu W.Y., Sun Z.W. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol Immunotoxicol 2011, 33(March (1)):211-219.
45. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., Smith L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 2007, 25(May (21)):4273-4282.
46. Huttner W.B., Schiebler W., Greengard P., De Camilli P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol 1983, 96(May (5)):1374-1388.
47. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 2007, 189(February (3)):818-832.
48. Marxen P., Fuhrmann U., Bigalke H. Gangliosides mediate inhibitory effects of tetanus and botulinum A neurotoxins on exocytosis in chromaffin cells. Toxicon 1989, 27(8):849-859.
49. Rummel A., Mahrhold S., Bigalke H., Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 2004, 51(February (3)):631-643.
50. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol 2007, 44(February (5)):1029-1041.
51. Pless D.D., Reinke R.G., Ulrich E.K., Bavari R.G.S. Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators. Infect Immun 2005, 73:5358-5366.
52. Dertzbaugh M.T., West M.W. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 1996, 14(November (16)):1538-1544.
53. Gzyl A., Augustynowicz E., van Loo I., Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine 2001, 20(November (3-4)):299-303.
54. Gzyl A., Augustynowicz E., Gniadek G., Rabczenko D., Dulny G., Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine 2004, 22(June (17-18)):2122-2128.
55. Storm M., Advani A., Pettersson M., Hallander H.O., Bondeson K. Comparison of real-time PCR and pyrosequencing for typing Bordetella pertussis toxin subunit 1 variants. J Microbiol Methods 2006, 65(April (1)):153-158.
56. Raffestin S., Marvaud J.C., Cerrato R., Dupuy B., Popoff M.R. Organization and regulation of the neurotoxin genes in Clostridium botulinum and Clostridium tetani. Anaerobe 2004, 10(April (2)):93-100.
57. Marshall K.M., Bradshaw M., Pellett S., Johnson E.A. Plasmid encoded neurotoxin genes in Clostridium botulinum serotype A subtypes. Biochem Biophys Res Commun 2007, 361(September (1)):49-54.